Two cases of portal-systemic encephalopathy caused by multiple portosystemic shunts successfully treated with percutaneous transhepatic obliteration
Tóm tắt
Portal-systemic encephalopathy is a hepatic encephalopathy caused by portosystemic shunts and is a poor prognostic factor for cirrhotic patients. Percutaneous transhepatic obliteration is an option for controlling portal-systemic encephalopathy. We report two cases of portal-systemic encephalopathy that were successfully controlled with percutaneous transhepatic obliteration. (Case 1) A 70-year-old woman experienced repeated portal-systemic encephalopathy due to a mesocaval shunt and a paraumbilical vein. She underwent percutaneous transhepatic obliteration with coils and 5% ethanolamine oleate-iopamidol. After treatment, portal-systemic encephalopathy became controllable. (Case 2) A 60-year-old man experienced repeated portal-systemic encephalopathy due to a left gastric vein shunt, a shunt from the posterior branch of the intrahepatic portal vein to the inferior phrenic vein, and a paraumbilical vein. He underwent percutaneous transhepatic obliteration of three portosystemic shunts with coils, 5% ethanolamine oleate-iopamidol, and N-butyl-2-cyanoacrylate. After treatment, the portal-systemic encephalopathy became controllable. Percutaneous transhepatic obliteration is particularly effective in cases involving multiple and complex portosystemic shunt pathways; however, percutaneous transhepatic obliteration is an invasive treatment, and its indications should be carefully considered. These cases will serve as a reference for successful treatment in the future cases.
Tài liệu tham khảo
Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy–definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th world congresses of gastroenterology, Vienna, 1998. Hepatology. 2002;35:716–21.
Sherlock S. Chronic portal systemic encephalopathy: update 1987. Gut. 1987;28:1043–8.
Kato T, Uematsu T, Nishigaki Y, et al. Therapeutic effect of balloon-occluded retrograde transvenous obliteration on portal-systemic encephalopathy in patients with liver cirrhosis. Intern Med. 2001;40:688–91.
Kawanaka H, Ohta M, Hashizume M, et al. Portosystemic encephalopathy treated with balloon-occluded retrograde transvenous obliteration. Am J Gastroenterol. 1995;90:508–10.
Fukuda T, Hirota S, Sugimura K. Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy. J Vasc Interv Radiol. 2001;12:327–36.
Inoue H, Emori K, Toyonaga A, et al. Long term results of balloon-occluded retrograde transvenous obliteration for portosystemic shunt encephalopathy in patients with liver cirrhosis and portal hypertension. Kurume Med J. 2014;61:1–8.
Lunderquist A, Vang J. Transhepatic catheterization and obliteration of the coronary vein in patients with portal hypertension and esophageal varices. N Engl J Med. 1974;291:646–9.
Ohta M, Hashizume M, Kawanaka H, et al. Complications of percutaneous transhepatic catheterization of the portal venous system in patients with portal hypertension. J Gastroenterol Hepatol. 1996;11:630–4.
Boku M, Sugimoto K, Nakamura T, et al. Percutaneous trans-hepatic obliteration for bleeding esophagojejunal varices after total gastrectomy and esophagojejunostomy. Cardiovasc Intervent Radiol. 2006;29:1152–5.
Chikamori F, Kuniyoshi N, Kagiyama S, et al. Role of percutaneous transhepatic obliteration for special types of varices with portal hypertension. Abdom Imaging. 2007;32:92–5.
Ishikawa T, Imai M, Endo S, et al. Effectiveness of different coils for endovascular coiling for intractable hepatic encephalopathy caused by a portosystemic shunt. Ann Palliat Med. 2022. https://doi.org/10.21037/apm-21-2594.
Takenaga S, Narita K, Matsui Y, et al. Hepatic encephalopathy due to congenital multiple intrahepatic portosystemic venous shunts successfully treated by percutaneous transhepatic obliteration. Case Rep Gastroenterol. 2016;10:701–5.
Ishikawa T, Imai M, Ko M, et al. Percutaneous transhepatic obliteration and percutaneous transhepatic sclerotherapy for intractable hepatic encephalopathy and gastric varices improves the hepatic function reserve. Biomed Rep. 2017;6:99–102.
Pereiras R, Viamonte M Jr, Russell E, et al. New techniques for interruption of gastroesophageal venous blood flow. Radiology. 1977;124:313–23.
Scott J, Dick R, Long RG, et al. Percutaneous transhepatic obliteration of gastro-oesophageal varices. Lancet. 1976;2:53–5.
Gimm G, Chang Y, Kim HC, et al. Balloon-occluded retrograde transvenous obliteration versus transjugular intrahepatic portosystemic shunt for the management of gastric variceal bleeding. Gut Liver. 2018;12:704–13.
Simonetto DA, Liu M, Kamath PS. Portal hypertension and related complications: diagnosis and management. Mayo Clin Proc. 2019;94:714–26.
Negishi Y, Tanaka A, Ishii H, et al. Contrast-Induced nephropathy and long-term clinical outcomes following percutaneous coronary intervention in patients with advanced renal dysfunction (estimated glomerular filtration rate <30 ml/min/1.73 m(2)). Am J Cardiol. 2019;123:361–7.
McDonald JS, McDonald RJ, Carter RE, et al. Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate. Radiology. 2014;271:65–73.
Tao SM, Kong X, Schoepf UJ, et al. Acute kidney injury in patients with nephrotic syndrome undergoing contrast-enhanced CT for suspected venous thromboembolism: a propensity score-matched retrospective cohort study. Eur Radiol. 2018;28:1585–93.
Sakurabayashi S, Sezai S, Yamamoto Y, et al. Embolization of portal-systemic shunts in cirrhotic patients with chronic recurrent hepatic encephalopathy. Cardiovasc Intervent Radiol. 1997;20:120–4.
Kobayakawa M, Kokubu S, Hirota S, et al. Short-term safety and efficacy of balloon-occluded retrograde transvenous obliteration using ethanolamine oleate: results of a prospective, multicenter single-arm trial. J Vasc Interv Radiol. 2017;28:1108-1115.e1102.
Okahara M, Kiyosue H, Ueda S, et al. Anatomic features and retrograde transvenous obliteration of duodenal varices associated with mesocaval collateral pathway. J Vasc Interv Radiol. 2012;23:1339–46.
Takeuchi Y, Morishita H, Sato Y, et al. Guidelines for the use of NBCA in vascular embolization devised by the committee of practice guidelines of the Japanese society of interventional radiology (CGJSIR), 2012 edition. Jpn J Radiol. 2014;32:500–17.
Miyaaki H, Ichikawa T, Taura N, et al. Endoscopic management of esophagogastric varices in Japan. Ann Transl Med. 2014;2:42.
Targarona EM. Portal vein thrombosis after laparoscopic splenectomy: the size of the risk. Surg Innov. 2008;15:266–70.
Uchiyama T, Hirokazu T, Hosono K, et al. Portal vein thrombosis treated using danaparoid sodium and antithrombin III. Hepatogastroenterology. 2010;57:52–3.
O’Connor SD, Taylor AJ, Williams EC, et al. Coagulation concepts update. AJR Am J Roentgenol. 2009;193:1656–64.
Saad WE. Balloon-occluded retrograde transvenous obliteration of gastric varices: concept, basic techniques, and outcomes. Semin Intervent Radiol. 2012;29:118–28.
Yokoyama K, Yamauchi R, Shibata K, et al. Endoscopic treatment or balloon-occluded retrograde transvenous obliteration is safe for patients with esophageal/gastric varices in child-pugh class C end-stage liver cirrhosis. Clin Mol Hepatol. 2019;25:183–9.
Fujiyama S, Saitoh S, Kawamura Y, et al. Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome. BMC Gastroenterol. 2017;17:112.
Hayashi T, Takatori H, Horii R, et al. Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients. BMC Gastroenterol. 2019;19:217.
Nagaoki Y, Aikata H, Daijyo K, et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res. 2018;48:51–8.
Priyanka P, Kupec JT, Krafft M, et al. Newer oral anticoagulants in the treatment of acute portal vein thrombosis in patients with and without cirrhosis. Int J Hepatol. 2018;2018:8432781.
Kockerling D, Nathwani R, Forlano R, et al. Current and future pharmacological therapies for managing cirrhosis and its complications. World J Gastroenterol. 2019;25:888–908.